The predictive value of serum soluble E-cadherin levels in breast cancer patients undergoing preoperative systemic chemotherapy

Clinical Biochemistry

Volumn 46, Issue 15, 2013, Pages 1585-1589

  Hofmann, G ^a   Balic, M ^a   Dandachi, N ^a   Resel, M ^a   Schippinger, W ^b   Regitnig, P ^a   Samonigg, H ^a   Bauernhofer, T ^b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Breast cancer; Chemotherapy; Predictive marker; Preoperative; Serum; Soluble E cadherin

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; HORMONE RECEPTOR; PACLITAXEL; UVOMORULIN;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BREAST CANCER; BREAST SURGERY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; ENZYME IMMUNOASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MENOPAUSE; METASTASIS; MULTIPLE CYCLE TREATMENT; PREDICTIVE VALUE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT RESPONSE; TUMOR VOLUME;

A DISINTEGRIN AND METALLOPROTEINASE; ADAM; BREAST CANCER; CHEMOTHERAPY; CLINICALLY MEASURED TUMOR SIZE; CT; DFS; DISEASE-FREE SURVIVAL; ERB-B; ERK; EXTRACELLULAR-SIGNAL-REGULATED KINASE; HER; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR; MATRIX-METALLO-PROTEINASE; MMP; OS; OVERALL SURVIVAL; PATHOLOGIC COMPLETE REMISSION; PCR; PREDICTIVE MARKER; PREOPERATIVE; PREOPERATIVE SYSTEMIC THERAPY; PST; RECEPTOR TYROSINE KINASE; SERUM; SOLUBLE E-CADHERIN; TNM-SYSTEM; TUMOR-NODE-METASTASIS CANCER STAGING SYSTEM;

ADULT; AGED; ANALYSIS OF VARIANCE; BREAST NEOPLASMS; CADHERINS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM GRADING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEOLYSIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SOLUBILITY; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84884351343     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2013.06.010     Document Type: Article

References (40)

1. Group EBCTC Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717.
2. De Lena M., Zucali R., Viganotti G., Valagussa P., Bonadonna G. Combined chemotherapy-radiotherapy approach in locally advanced (t3b-t4) breast cancer. Cancer Chemother Pharmacol 1978, 1:53-59.
3. Wolff A.C., Davidson N.E. Primary systemic therapy in operable breast cancer. J Clin Oncol 2000, 18:1558-1569.
4. Bear H.D., Anderson S., Smith R.E., Geyer C.E., Mamounas E.P., Fisher B., et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: national surgical adjuvant breast and bowel project protocol b-27. J Clin Oncol 2006, 24:2019-2027.
5. Fisher B., Bryant J., Wolmark N., Mamounas E., Brown A., Fisher E.R., et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998, 16:2672-2685.
6. Mathew J., Asgeirsson K.S., Cheung K.L., Chan S., Dahda A., Robertson J.F. Neoadjuvant chemotherapy for locally advanced breast cancer: a review of the literature and future directions. Eur J Surg Oncol 2009, 35:113-122.
7. Tewari M., Krishnamurthy A., Shukla H.S. Predictive markers of response to neoadjuvant chemotherapy in breast cancer. Surg Oncol 2008, 17:301-311.
8. Bryant D.M., Stow J.L. The ins and outs of E-cadherin trafficking. Trends Cell Biol 2004, 14:427-434.
9. Gumbiner B.M. Regulation of cadherin-mediated adhesion in morphogenesis. Nat Rev Mol Cell Biol 2005, 6:622-634.
10. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991, 251:1451-1455.
11. Andrews J.L., Kim A.C., Hens J.R. The role and function of cadherins in the mammary gland. Breast Cancer Res 2012, 14:203.
12. Beavon I.R. The E-cadherin-catenin complex in tumour metastasis: structure, function and regulation. Eur J Cancer 2000, 36:1607-1620.
13. Doki Y., Shiozaki H., Tahara H., Inoue M., Oka H., Iihara K., et al. Correlation between E-cadherin expression and invasiveness in vitro in a human esophageal cancer cell line. Cancer Res 1993, 53:3421-3426.
14. Liu Y.N., Lee W.W., Wang C.Y., Chao T.H., Chen Y., Chen J.H. Regulatory mechanisms controlling human E-cadherin gene expression. Oncogene 2005, 24:8277-8290.
15. Paredes J., Figueiredo J., Albergaria A., Oliveira P., Carvalho J., Ribeiro A.S., et al. Epithelial e- and p-cadherins: role and clinical significance in cancer. Biochim Biophys Acta 1826, 2012:297-311.
16. Rodriguez F.J., Lewis-Tuffin L.J., Anastasiadis P.Z. E-cadherin's dark side: possible role in tumor progression. Biochim Biophys Acta 1826, 2012:23-31.
17. Marambaud P., Shioi J., Serban G., Georgakopoulos A., Sarner S., Nagy V., et al. A presenilin-1/gamma-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. EMBO J 2002, 21:1948-1956.
18. Najy A.J., Day K.C., Day M.L. The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation. J Biol Chem 2008, 283:18393-18401.
19. Rios-Doria J., Day K.C., Kuefer R., Rashid M.G., Chinnaiyan A.M., Rubin M.A., et al. The role of calpain in the proteolytic cleavage of E-cadherin in prostate and mammary epithelial cells. J Biol Chem 2003, 278:1372-1379.
20. Grabowska M.M., Sandhu B., Day M.L. Egf promotes the shedding of soluble E-cadherin in an ADAM10-dependent manner in prostate epithelial cells. Cell Signal 2012, 24:532-538.
21. Grabowska M.M., Day M.L. Soluble E-cadherin: more than a symptom of disease. Front Biosci 2012, 17:1948-1964.
22. Katayama M., Hirai S., Kamihagi K., Nakagawa K., Yasumoto M., Kato I. Soluble E-cadherin fragments increased in circulation of cancer patients. Br J Cancer 1994, 69:580-585.
23. Parrish A.R., Catania J.M., Orozco J., Gandolfi A.J. Chemically induced oxidative stress disrupts the E-cadherin/catenin cell adhesion complex. Toxicol Sci 1999, 51:80-86.
24. Perry I., Tselepis C., Hoyland J., Iqbal T.H., Scott D., Sanders S.A., et al. Reduced cadherin/catenin complex expression in celiac disease can be reproduced in vitro by cytokine stimulation. Lab Invest 1999, 79:1489-1499.
25. Karayiannakis A.J., Syrigos K.N., Savva A., Polychronidis A., Karatzas G., Simopoulos C. Serum E-cadherin concentrations and their response during laparoscopic and open cholecystectomy. Surg Endosc 2002, 16:1551-1554.
26. Chan A.O., Chu K.M., Lam S.K., Cheung K.L., Law S., Kwok K.F., et al. Early prediction of tumor recurrence after curative resection of gastric carcinoma by measuring soluble E-cadherin. Cancer 2005, 104:740-746.
27. Charalabopoulos K., Gogali A., Dalavaga Y., Daskalopoulos G., Vassiliou M., Bablekos G., et al. The clinical significance of soluble E-cadherin in nonsmall cell lung cancer. Exp Oncol 2006, 28:83-85.
28. Griffiths T.R., Brotherick I., Bishop R.I., White M.D., McKenna D.M., Horne C.H., et al. Cell adhesion molecules in bladder cancer: soluble serum E-cadherin correlates with predictors of recurrence. Br J Cancer 1996, 74:579-584.
29. Matsumoto K., Shariat S.F., Casella R., Wheeler T.M., Slawin K.M., Lerner S.P. Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy. J Urol 2003, 170:2248-2252.
30. Soyama A., Eguchi S., Takatsuki M., Kawashita Y., Hidaka M., Tokai H., et al. Significance of the serum level of soluble E-cadherin in patients with HCC. Hepatogastroenterology 2008, 55:1390-1393.
31. Syrigos K.N., Harrington K.J., Karayiannakis A.J., Baibas N., Katirtzoglou N., Roussou P. Circulating soluble E-cadherin levels are of prognostic significance in patients with multiple myeloma. Anticancer Res 2004, 24:2027-2031.
32. De Wever O., Derycke L., Hendrix A., De Meerleer G., Godeau F., Depypere H., et al. Soluble cadherins as cancer biomarkers. Clin Exp Metastasis 2007, 24:685-697.
33. Sinn H.P., Schmid H., Junkermann H., Huober J., Leppien G., Kaufmann M., et al. Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy. Geburtshilfe Frauenheilkd 1994, 54:552-558.
34. Knudsen K.A., Lin C.Y., Johnson K.R., Wheelock M.J., Keshgegian A.A., Soler A.P. Lack of correlation between serum levels of E- and P-cadherin fragments and the presence of breast cancer. Hum Pathol 2000, 31:961-965.
35. Carvalho C., Santos R.X., Cardoso S., Correia S., Oliveira P.J., Santos M.S., et al. Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem 2009, 16:3267-3285.
36. Chen B., Peng X., Pentassuglia L., Lim C.C., Sawyer D.B. Molecular and cellular mechanisms of anthracycline cardiotoxicity. Cardiovasc Toxicol 2007, 7:114-121.
37. Nawrocki-Raby B., Gilles C., Polette M., Bruyneel E., Laronze J.Y., Bonnet N., et al. Upregulation of MMPs by soluble E-cadherin in human lung tumor cells. Int J Cancer 2003, 105:790-795.
38. Wheelock M.J., Buck C.A., Bechtol K.B., Damsky C.H. Soluble 80-kd fragment of cell-CAM 120/80 disrupts cell-cell adhesion. J Cell Biochem 1987, 34:187-202.
39. Alaoui-Jamali M.A., Paterson J., Al Moustafa A.E., Yen L. The role of ErbB-2 tyrosine kinase receptor in cellular intrinsic chemoresistance: mechanisms and implications. Biochem Cell Biol 1997, 75:315-325.
40. Trudeau M., Sinclair S.E., Clemons M. Neoadjuvant taxanes in the treatment of non-metastatic breast cancer: a systematic review. Cancer Treat Rev 2005, 31:283-302.